

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/626,943
				Filing Date	July 25, 2003
				First Named Inventor	Rubino
				Group Art Unit	1614
				Examiner Name	G. Polansky
Sheet	1	of	3	Attorney Docket Number	AM-100802

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	1	WO-94/02136	02-03-1994	Smithkline Beecham Corp.		
	2	WO-00/33878	06-15-2000	Novartis		
	3	WO-98/30205	07-16-1998	Sonus Pharma. Inc.		
	4	WO-99/45918	09-16-1999	Naphro Biotherapeutics, Inc.		

Examiner Signature	/Gregg Polansky/	Date Considered	11/03/2009
--------------------	------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/626,943
				Filing Date	July 25, 2003
				First Named Inventor	Rubino
				Group Art Unit	1614
				Examiner Name	G. Polansky
Sheet	2	of	3	Attorney Docket Number	AM-100802

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²	
	5	FIEDLER, H. <i>Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete</i> , vol. 2, no. 4, Auglage, pp. 1210-1217, Cantor-Verlag, Aulendorf, Deutschland, 1996.		
	6	PODSYPANINA, K, An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten ^{+/-} mice, PNAS, vol. 98, no. 18, pp. 10320-10325, August 2001.		
	7	SWEETANA, S. AND AKERS, M., Solubility principles and practices for parenteral drug dosage form development, PDA Journal of Pharmaceutical Science and Technology, vol. 50, no. 5, pp. 330-342, September 1996.		
	8	STRICKLEY, R., Parenteral formulations of small molecules therapeutics marketed in the United States (1999) Part I, Journal of Pharmaceutical Science and Technology, vol. 53, no. 6, pp. 324-349, November 1999.		
	9	POWELL, M., Compendium of Excipients for Parenteral Formulations, PDA Journal of Pharmaceutical Science and Technology, vol. 52, no. 5, pp. 238-311, November 1999.		
	10	SORBERA, L.A., et al, CCI-779 Oncolytic mTOR inhibitor, Drugs of the Future, vol. 27, no. 1, pp. 7-13, January 2002.		
	11	Wyeth Pharmaceuticals Inc, HIGHLIGHTS OF PRESCRIBING INFORMATION, (Torisel, temsirolimus), Philadelphia, USA, May 2007.		
	12	GARBER, K., Rapamycin's Resurrection: A new way to target the cancer cell cycle, J. National Cancer Institute, vol. 93, no. 20, pp. 1517-1519, October 2001.		
	13	GRUNWALD, V., et al, Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells, Cancer Research, vol. 62, pp. 6141-6145, November 2002.		
	14	DUDKIN, Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clinical Cancer Research, vol. 7, pp. 1758-1764, June 2001.		
	15	GEORGER, Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination therapy, Cancer Research, vol. 61, pp. 1527-1532, February 2001.		
	16	"Solution Formulations" in Pharmaceutical Preformulation and Formulation, 2001, pp. 196-210.		

Examiner Signature	/Gregg Polansky/	Date Considered	11/03/2009
--------------------	------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450

/G.P./

Receipt date: 09/16/2009

10626943 - GAU: 1614

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/626,943
				Filing Date	July 25, 2003
				First Named Inventor	Rubino
				Group Art Unit	1614
				Examiner Name	G. Polansky
Sheet	3	of	3	Attorney Docket Number	AM-100802

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published	T ²
	17	MENDENHALL, Stability of Parenterals, Drug Development and Industrial Pharmacy, vol. 10, no. 8-9, pp. 1297-1342, October 1984.	
	18	YU, mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer, Endocrine-Related Cancer, vol. 8, pp. 249-258, September 2001.	

Examiner Signature	/Gregg Polansky/	Date Considered	11/03/2009
--------------------	------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.P./